LT2279007T - Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai - Google Patents

Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai

Info

Publication number
LT2279007T
LT2279007T LTEP09738181.8T LT09738181T LT2279007T LT 2279007 T LT2279007 T LT 2279007T LT 09738181 T LT09738181 T LT 09738181T LT 2279007 T LT2279007 T LT 2279007T
Authority
LT
Lithuania
Prior art keywords
growth hormone
recombinant human
human growth
pegylated recombinant
hormone compounds
Prior art date
Application number
LTEP09738181.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Harald Rau
Susanne Kindermann
Torben Lessmann
Grethe Norskov Rasmussen
Ulrich Hersel
Thomas Wegge
Kennett SPROG E
Original Assignee
Ascendis Pharma Growth Disorders Division A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08155408A external-priority patent/EP2113256A1/de
Application filed by Ascendis Pharma Growth Disorders Division A/S filed Critical Ascendis Pharma Growth Disorders Division A/S
Publication of LT2279007T publication Critical patent/LT2279007T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
LTEP09738181.8T 2008-04-29 2009-04-29 Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai LT2279007T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08155408A EP2113256A1 (de) 2008-04-29 2008-04-29 Pegylierte rhGH-Verbindungen
EP08162865 2008-08-22
EP08167289 2008-10-22
PCT/EP2009/055194 WO2009133137A2 (en) 2008-04-29 2009-04-29 Pegylated recombinant human growth hormone compounds

Publications (1)

Publication Number Publication Date
LT2279007T true LT2279007T (lt) 2016-10-10

Family

ID=40872078

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16156852.2T LT3050576T (lt) 2008-04-29 2009-04-29 Pegiliuoti rekombinantinio žmogaus augimo hormono junginiai
LTEP09738181.8T LT2279007T (lt) 2008-04-29 2009-04-29 Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP16156852.2T LT3050576T (lt) 2008-04-29 2009-04-29 Pegiliuoti rekombinantinio žmogaus augimo hormono junginiai

Country Status (20)

Country Link
US (4) US9272048B2 (de)
EP (3) EP3050576B1 (de)
JP (5) JP6112766B2 (de)
CN (2) CN102989001B (de)
BR (1) BRPI0911780B1 (de)
CA (3) CA3004716C (de)
CY (2) CY1117882T1 (de)
DK (2) DK2279007T3 (de)
ES (2) ES2587400T3 (de)
HK (2) HK1152239A1 (de)
HR (2) HRP20161040T1 (de)
HU (2) HUE054585T2 (de)
IL (2) IL208833A (de)
LT (2) LT3050576T (de)
MX (2) MX344559B (de)
PL (2) PL3050576T3 (de)
PT (2) PT2279007T (de)
RU (1) RU2689336C2 (de)
SI (2) SI2279007T1 (de)
WO (1) WO2009133137A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377917B2 (en) * 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
PT2279007T (pt) * 2008-04-29 2016-08-23 Ascendis Pharma Growth Disorders Div As Compostos recombinantes e peguilados da hormona de crescimento humana
WO2009158668A1 (en) * 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
CN104740631B (zh) 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
US8986609B2 (en) 2009-10-29 2015-03-24 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
WO2011073234A2 (en) * 2009-12-15 2011-06-23 Ascendis Pharma As Growth hormone composition
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2525829A1 (de) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptidbasierte prodrug-linker für aromatische aminhaltige arzneimittel
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN108314733A (zh) * 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
MX349950B (es) 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
WO2013024051A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Sustained release composition of prostacyclin
KR20140101397A (ko) 2011-12-09 2014-08-19 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
SG11201501920PA (en) 2012-10-11 2015-04-29 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
CN104884093A (zh) 2012-12-07 2015-09-02 阿森迪斯药物股份有限公司 载体连接型前列腺素类前药
CN103976982A (zh) * 2014-06-03 2014-08-13 长春理工大学 一种包载重组人生长激素缓释药物微囊
IL307773A (en) * 2014-11-18 2023-12-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric human growth hormone drug matrices
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN115025239A (zh) * 2016-03-01 2022-09-09 阿森迪斯药物骨疾病股份有限公司 Pth前药
ES2943720T3 (es) 2016-09-29 2023-06-15 Ascendis Pharma Bone Diseases As Compuestos de PTH con bajas relaciones de pico a valle
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
MA46428A (fr) * 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases As Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
MX2020009857A (es) * 2018-03-28 2021-01-08 Ascendis Pharma Oncology Div A/S Conjugados de interleucina-2 (il-2).
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
BR112022022826A2 (pt) 2020-06-03 2022-12-13 Ascendis Pharma Oncology Div A/S Sequências de il-2 e usos das mesmas
MX2023002047A (es) 2020-08-28 2023-03-15 Ascendis Pharma Oncology Div A/S Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas.
CN112362643A (zh) * 2020-11-09 2021-02-12 长春金赛药业有限责任公司 一种基于镧系元素化学发光法长效生长激素免疫定量检测试剂盒及其方法
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU1825299A (en) 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
EP1243276A1 (de) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ATE337017T1 (de) 2002-11-15 2006-09-15 Hoffmann La Roche Positionelle isomeren von pegyliertem interferon alpha 2a
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
EP1525890A1 (de) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophor Komplex
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EP1625855A1 (de) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymerische Prodrogen mit einer selbstimmolativen Verknüpfung
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1579873A1 (de) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymerische Prodrogen mit einer selbstimmolativen Verknüpfung
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
JP2008531482A (ja) * 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
EP1893239A2 (de) * 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Durch transglutaminase vermittelte konjugation von wachstumshormon
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
PT2279007T (pt) * 2008-04-29 2016-08-23 Ascendis Pharma Growth Disorders Div As Compostos recombinantes e peguilados da hormona de crescimento humana
WO2011073234A2 (en) * 2009-12-15 2011-06-23 Ascendis Pharma As Growth hormone composition
WO2016079302A1 (en) * 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms

Also Published As

Publication number Publication date
CY1124332T1 (el) 2022-07-22
PT3050576T (pt) 2021-06-01
CN102014965A (zh) 2011-04-13
RU2689336C2 (ru) 2019-05-27
HRP20210839T1 (hr) 2021-08-20
EP2279007B1 (de) 2016-05-18
IL228673A0 (en) 2013-12-31
MX344559B (es) 2016-12-20
SI2279007T1 (sl) 2016-09-30
RU2014129893A (ru) 2016-02-10
HUE029926T2 (en) 2017-04-28
BRPI0911780A8 (pt) 2018-03-06
US9272048B2 (en) 2016-03-01
JP2011518863A (ja) 2011-06-30
CA3004716C (en) 2022-04-12
HK1179899A1 (en) 2013-10-11
US20190192634A1 (en) 2019-06-27
JP6179997B2 (ja) 2017-08-16
JP6151165B2 (ja) 2017-06-21
CA2721947C (en) 2016-03-08
PL2279007T3 (pl) 2016-11-30
IL228673A (en) 2014-06-30
WO2009133137A3 (en) 2009-12-23
EP2279007A2 (de) 2011-02-02
JP2018150311A (ja) 2018-09-27
WO2009133137A2 (en) 2009-11-05
PL3050576T3 (pl) 2021-10-25
CA2915677A1 (en) 2009-11-05
US20110112021A1 (en) 2011-05-12
EP3922267A1 (de) 2021-12-15
CA3004716A1 (en) 2009-11-05
CA2721947A1 (en) 2009-11-05
JP6112766B2 (ja) 2017-04-12
CN102014965B (zh) 2015-11-25
CN102989001B (zh) 2014-12-03
ES2875426T3 (es) 2021-11-10
US10960053B2 (en) 2021-03-30
BRPI0911780B1 (pt) 2021-10-05
ES2587400T3 (es) 2016-10-24
RU2019114484A (ru) 2020-11-16
HRP20161040T1 (hr) 2016-12-16
JP2016029072A (ja) 2016-03-03
SI3050576T1 (sl) 2021-08-31
HUE054585T2 (hu) 2021-09-28
US10098930B2 (en) 2018-10-16
HK1152239A1 (zh) 2012-02-24
PT2279007T (pt) 2016-08-23
RU2010148308A (ru) 2012-06-10
MX2010011800A (es) 2011-06-20
JP6329673B2 (ja) 2018-05-23
CA2915677C (en) 2018-06-26
CY1117882T1 (el) 2017-05-17
EP3050576A1 (de) 2016-08-03
US20210220442A1 (en) 2021-07-22
LT3050576T (lt) 2021-07-12
EP3050576B1 (de) 2021-03-31
DK3050576T3 (da) 2021-06-07
IL208833A (en) 2013-11-28
JP2014077002A (ja) 2014-05-01
JP2018021019A (ja) 2018-02-08
DK2279007T3 (en) 2016-08-22
JP6704429B2 (ja) 2020-06-03
AU2009242122A1 (en) 2009-11-05
IL208833A0 (en) 2011-01-31
RU2530714C2 (ru) 2014-10-10
BRPI0911780A2 (pt) 2015-10-06
CN102989001A (zh) 2013-03-27
US20160206702A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
IL228673A0 (en) Recombinant human growth hormone compounds modified with polyethylene glycol
HK1223946A1 (zh) 生物活性肽
SG10201608059VA (en) Recombinant vwf formulations
EP2298801A4 (de) Glykosyliertes glp-1-peptid
EP2307038A4 (de) Elastinartige peptide umfassende therapeutische mittel
HRP20130414T1 (en) Lyophilized recombinant vwf formulations
ZA201209436B (en) Improved recombinant human follicle-stimulating hormone
HK1244426A1 (zh) 治療性蛋白質製劑
IL202225A0 (en) Growth hormone fusion proteins
PL2464208T3 (pl) Kombajn zbożowy
ZA201105419B (en) Stable growth hormone compounds
EP2133090A4 (de) Wachstumshormon-sekretionsstimulator
EP2310035A4 (de) Fibroblasten-wachstumsfaktor (fgf) analoga und ihre verwendungen
IL223030A (en) Receptor receptor-1 growth factor-1 insulin-like peptides
EP2254901A4 (de) Therapeutische peptide
IL203073A0 (en) Modified growth hormone polypeptides
AU2009242122B2 (en) Pegylated recombinant human growth hormone compounds
GB0625888D0 (en) Growth hormone variations
GB201004015D0 (en) Growth hormone receptor polypeptide
GB0921430D0 (en) Protein for therapeutic use